Fate Therapeutics Q2 2024 Adj EPS $(0.33) Beats $(0.48) Estimate, Sales $6.80M Beat $1.41M Estimate
Author: Benzinga Newsdesk | August 13, 2024 04:09pm
Fate Therapeutics (NASDAQ:
FATE) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.48) by 31.25 percent. The company reported quarterly sales of $6.80 million which beat the analyst consensus estimate of $1.41 million by 382.73 percent. This is a 628.83 percent increase over sales of $933.00 thousand the same period last year.
Posted In: FATE